Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Bavarian Nordic A/S
  6. News
  7. Summary
    BAVA   DK0015998017

BAVARIAN NORDIC A/S

(BAVA)
  Report
Real-time Estimate Cboe Europe  -  03:08 2022-12-06 am EST
233.85 DKK   -0.74%
11/24Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
GL
11/24Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
AQ
11/23Global markets live: UBS, Apple, Nordstrom, Autodesk, Vmware...
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Britain says monkeypox shot offers strong 78% protection

11/22/2022 | 11:08am EST
Illustration shows test tubes labelled

LONDON (Reuters) - A single dose of the monkeypox vaccine provides 78% protection against the virus, according to data from England released on Tuesday that health officials said was the strongest evidence yet of its effectiveness.

Monkeypox cases have remained low but the World Health Organisation continues to classify the disease as a global health emergency, its highest level of alert.

The new analysis reviewed data for the Bavarian Nordic vaccine in England between July 4-Nov. 3, the UK Health Security Agency (UKHSA) said.

The single shot provides 78% protection 14 days after being vaccinated, while a second dose is expected to offer even greater and longer lasting protection, the UKHSA added.

More than 55,000 doses of the vaccine have been delivered so far, the agency said.

Monkeypox, a relatively mild viral illness that is endemic in several countries in western and central Africa, exploded around the world earlier this year.

There have since been more than 80,000 cases worldwide, according to the U.S. Centers for Disease Control and Prevention.

(Reporting by Sachin Ravikumar; Editing by Kate Holton)


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BAVARIAN NORDIC A/S -2.40% 235.6 Delayed Quote.-12.35%
DOW JONES AFRICA TITANS 50 INDEX -0.41% 471.95 Real-time Quote.-11.69%
S&P AFRICA 40 INDEX 0.01% 155.36 Real-time Quote.-10.89%
All news about BAVARIAN NORDIC A/S
11/24Report of transactions of shares and related securities of Bavarian Nordic by persons h..
GL
11/24Report of transactions of shares and related securities of Bavarian Nordic by persons h..
AQ
11/23Global markets live: UBS, Apple, Nordstrom, Autodesk, Vmware...
MS
11/23Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
GL
11/23Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
GL
11/22Bavarian Nordic's Monkeypox Vaccine Shows 78% Efficacy In New UK Analysis
MT
11/22Britain says monkeypox shot offers strong 78% protection
RE
11/18Vaccines and drugs in the pipeline for RSV
RE
11/17Bavarian Nordic Wins New Supply Contract for Monkeypox Jab With EU Pandemic Response Ag..
MT
11/17EU secures up to 2 million monkeypox vaccine doses from Bavarian Nordic
RE
More news
Analyst Recommendations on BAVARIAN NORDIC A/S
More recommendations
Financials
Sales 2022 3 092 M 437 M 437 M
Net income 2022 -606 M -85,7 M -85,7 M
Net cash 2022 1 759 M 249 M 249 M
P/E ratio 2022 -27,5x
Yield 2022 -
Capitalization 16 631 M 2 351 M 2 351 M
EV / Sales 2022 4,81x
EV / Sales 2023 1,41x
Nbr of Employees 917
Free-Float 99,8%
Chart BAVARIAN NORDIC A/S
Duration : Period :
Bavarian Nordic A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAVARIAN NORDIC A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 235,60 DKK
Average target price 400,57 DKK
Spread / Average Target 70,0%
EPS Revisions
Managers and Directors
Paul Chaplin President & Chief Executive Officer
Henrik Neilsen Juuel Chief Financial Officer & Executive Vice President
Gerardus Wilhelmus van Odijk Chairman
Laurence de Moerlooze Chief Medical Officer & Executive Vice President
Russell Thirsk Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
BAVARIAN NORDIC A/S-12.35%2 351
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY35.67%356 089
ABBVIE INC.21.08%289 331
NOVO NORDISK A/S22.53%287 688
PFIZER, INC.-13.78%285 774